Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 6
2000 1
2001 2
2006 9
2010 1
2012 1
2014 1
2020 14
2021 94
2022 1019
2023 49116
2024 21089

Text availability

Article attribute

Article type

Publication date

Search Results

65,910 results

Results by year

Filters applied: . Clear all
Quoted phrases not found in phrase index: "COVID-19 vaccine", "COVID-19 serotherapy", "COVID-19 diagnostic testing", "COVID-19", "COVID-19 drug treatment", "severe acute respiratory syndrome coronavirus 2"
Page 1
SARS-CoV-2 biology and host interactions.
Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, Kelly JN, Thiel V. Steiner S, et al. Nat Rev Microbiol. 2024 Apr;22(4):206-225. doi: 10.1038/s41579-023-01003-z. Epub 2024 Jan 15. Nat Rev Microbiol. 2024. PMID: 38225365 Review.
The zoonotic emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing coronavirus disease 2019 (COVID-19) pandemic have profoundly affected our society. The …
The zoonotic emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- …
COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences.
Scholkmann F, May CA. Scholkmann F, et al. Pathol Res Pract. 2023 Jun;246:154497. doi: 10.1016/j.prp.2023.154497. Epub 2023 May 3. Pathol Res Pract. 2023. PMID: 37192595 Free PMC article. Review.
Worldwide there have been over 760 million confirmed coronavirus disease 2019 (COVID-19) cases, and over 13 billion COVID-19 vaccine doses have been administered as of April 2023, according to the World Health Organization. An infection w …
Worldwide there have been over 760 million confirmed coronavirus disease 2019 (COVID-19) cases, and over 13 bill …
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD. Wang Q, et al. Nature. 2023 Dec;624(7992):639-644. doi: 10.1038/s41586-023-06750-w. Epub 2023 Oct 23. Nature. 2023. PMID: 37871613
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.2.86, has emerged and spread to numerous countries worldwide, raising alarm because its spike protein contains 34 additional mutati …
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvar …
Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY, Abi Fadel F, Huang S, Milinovich AT, Sacha GL, Bartley P, Duggal A, Wang X. Lin DY, et al. JAMA Netw Open. 2023 Sep 5;6(9):e2335077. doi: 10.1001/jamanetworkopen.2023.35077. JAMA Netw Open. 2023. PMID: 37733342 Free PMC article.
The associations of these 2 oral antiviral drugs with hospitalization and death resulting from infection with new SARS-CoV-2 Omicron subvariants, particularly BQ.1.1 and XBB.1.5, are unknown. ...The association of either nirmatrelvir or molnupiravir us …
The associations of these 2 oral antiviral drugs with hospitalization and death resulting from infection with new SARS-CoV …
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters.
Zhang L, Jiang Y, He J, Chen J, Qi R, Yuan L, Shao T, Zhao H, Chen C, Chen Y, Wang X, Lei X, Gao Q, Zhuang C, Zhou M, Ma J, Liu W, Yang M, Fu R, Wu Y, Chen F, Xiong H, Nie M, Chen Y, Wu K, Fang M, Wang Y, Zheng Z, Huang S, Ge S, Cheng SC, Zhu H, Cheng T, Yuan Q, Wu T, Zhang J, Chen Y, Zhang T, Li C, Qi H, Guan Y, Xia N. Zhang L, et al. Nat Commun. 2023 Jul 11;14(1):4117. doi: 10.1038/s41467-023-39560-9. Nat Commun. 2023. PMID: 37433761 Free PMC article.
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID …
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …
A systematic review and meta-analysis of long COVID symptoms.
Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, Rathod S, Halabi S, Elliot K, Shi JQ, Phiri P. Natarajan A, et al. Syst Rev. 2023 May 27;12(1):88. doi: 10.1186/s13643-023-02250-0. Syst Rev. 2023. PMID: 37245047 Free PMC article. Review.
BACKGROUND: Ongoing symptoms or the development of new symptoms following a SARS-CoV-2 diagnosis has caused a complex clinical problem known as "long COVID" (LC). ...The systematic review included publications from the 1st of December 2019 …
BACKGROUND: Ongoing symptoms or the development of new symptoms following a SARS-CoV-2 diagnosis has caused a co …
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.
Zhang P, Falcone S, Tsybovsky Y, Singh M, Gopan V, Miao H, Seo Y, Rogers D, Renzi I, Lai YT, Narayanan E, Stewart-Jones G, Himansu S, Carfi A, Fauci AS, Lusso P. Zhang P, et al. Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2305896120. doi: 10.1073/pnas.2305896120. Epub 2023 Jul 10. Proc Natl Acad Sci U S A. 2023. PMID: 37428933 Free PMC article.
Here, we applied the same principle to the design of a VLP-forming mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To promote cognate interaction with simian immunodeficiency virus ( …
Here, we applied the same principle to the design of a VLP-forming mRNA vaccine against severe acute respiratory syn …
Inability to work following COVID-19 vaccination-a relevant aspect for future booster vaccinations.
Reusch J, Wagenhäuser I, Gabel A, Höhn A, Lâm TT, Krone LB, Frey A, Schubert-Unkmeir A, Dölken L, Frantz S, Kurzai O, Vogel U, Krone M, Petri N. Reusch J, et al. Public Health. 2023 Sep;222:186-195. doi: 10.1016/j.puhe.2023.07.008. Epub 2023 Aug 8. Public Health. 2023. PMID: 37562083
OBJECTIVES: COVID-19 vaccination is a key prevention strategy to reduce the spread and severity of SARS-CoV-2 infections. ...RESULTS: Among 1704 HCWs enrolled, 595 (34.9%) HCWs were on sick leave following at least one COVID-19 vac …
OBJECTIVES: COVID-19 vaccination is a key prevention strategy to reduce the spread and severity of SARS-CoV-2 …
SARS-CoV-2 vaccines and myocarditis.
Sularz AK, Hua A, Ismail T. Sularz AK, et al. Clin Med (Lond). 2023 Sep;23(5):495-502. doi: 10.7861/clinmed.2023-0049. Epub 2023 Sep 29. Clin Med (Lond). 2023. PMID: 37775180 Free PMC article. Review.
The development of safe and effective vaccines against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a major turning point in the fight against the Coronavirus 2019 (COVID-19 …
The development of safe and effective vaccines against severe acute respiratory syndrome-coronavirus 2 …
SARS-CoV-2 spike S2-specific neutralizing antibodies.
Li CJ, Chang SC. Li CJ, et al. Emerg Microbes Infect. 2023 Dec;12(2):2220582. doi: 10.1080/22221751.2023.2220582. Emerg Microbes Infect. 2023. PMID: 37254830 Free PMC article. Review.
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed …
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against s …
65,910 results
You have reached the last available page of results. Please see the User Guide for more information.